

C U R R I C U L U M V I T A E

Valentina Camera



PERSONAL DETAILS

Date of birth: 09/06/1990

Place of birth: Verona, Italy

Citizenship: Italian

Address: via Michelotto Attendolo n 12

Telephone: +393318002600

E-mail: valentinacamerak@gmail.com / valentina.camera@univr.it

[http:// orcid. org/ 0000- 0002- 4925- 9000](http://orcid.org/0000-0002-4925-9000)

CURRENT POSITION

PhD candidate
Department of Neuroscience, Biomedicine and Movement sciences
University of Verona
Verona
Italy

EDUCATION

03/03/2020 - 01/11/2021: NMO clinical and research fellow - Department of Clinical Neuroscience - John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust -Oxford, United Kingdom

26/10/2020 Neurology Specialty

Awarded at University of Modena e Reggio Emilia, Modena, Italy.

Final thesis: "Early predictors of long-term disability of paediatric onset aquaporin-4-antibody positive Neuromyelitis Optica Spectrum Disorders" (performed at University of Modena and Reggio Emilia and University of Oxford). Supervisors: Prof. Stefano Meletti, Prof. Jacqueline Palace. Mark: 110/110 cum laude.

11/2016-10/2020: Neurology Training at Neurology Unit, Ospedale Civile Sant'Agostino Estense, Modena, Italy. During the training 7 months spent in training at the **Multiple Sclerosis and demyelinating disorders specialized centre of Modena**

23/02/2016 License to Practice as Surgeon and registration at Ordine dei Medici, Chirurghi e Odontoiatri di Verona (OMCEOVR), Verona, Italy

04/02/2016 State Exam Diploma: University of Verona, Verona, Italy

15/07/2015 Combined Bachelor's + Master's Degree in Medicine and Surgery
Awarded at University of Verona, Verona, Italy.

Final thesis: "Caratteristiche cliniche, cognitive e MRI a lungo termine di pazienti con Sclerosi Multipla benigna non trattata: uno studio di storia naturale".

Supervisors: Prof. Salvatore Monaco, Dr. Alberto Gajofatto. Mark: 110/110 cum laude.

| | |
|---|---|
| | 13/07/2009 Maturità Scientifica Diploma at Liceo Scientifico “Angelo Messedaglia”, Verona, Italy |
| SCIENTIFIC AFFILIATIONS | <p>11/2020-ongoing Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, United Kingdom</p> <p>11/2016-11/2020 Department of Biomedical, Metabolic science and Neuroscience, University of Modena and Reggio Emilia, Modena, Italy</p> <p>2015-2016 Department of Neuroscience, Biomedicina e Movimento University of Verona</p> |
| AREAS OF RESEARCH | <p>Clinical research, advanced MRI research on Paediatric and Adult inflammatory demyelinating diseases of the central nervous system as multiple sclerosis, MOG-antibody disease, and aquaporin-4 antibody neuromyelitis optica.</p> <p>Clinical and laboratory biomarkers in multiple sclerosis</p> |
| INTERNATIONAL EXPERIENCES AND COLLABORATIONS | <p>11/2020-11/2021 European Charcot Foundation research fellowship Projects as principal investigator:</p> <ol style="list-style-type: none"> 1) Prognostic factors in paediatric-onset aquaporin-4 antibody Neuromyelitis Optica: a UK multi-centre study 2) Pathophysiology of fatigue in multiple sclerosis, MOG-antibody disease, and aquaporin-4 disease: advanced MRI comparison analysis <p>Fellowship at the UK National Neuromyelitis Optica Centre, John Radcliffe Hospital, Oxford University Hospitals Foundation NHS Trust, Oxford, United Kingdom (one year fellowship)</p> <p>03/2020-09/2020 ERASMUS clinical traineeship: the UK National Neuromyelitis Optica Centre, John Radcliffe Hospital, Oxford University Hospitals Foundation NHS Trust, Oxford, United Kingdom</p> |

| | |
|----------------------------|---|
| <p>PUBLICATIONS</p> | <p>Heterogeneity of Cortical Lesion Susceptibility Mapping in Multiple Sclerosis. <i>AJNR Am J Neuroradiol</i> 2017 Jun;38(6):1087- 1095. DOI: 10.3174/ajnr. A5150 (CO-AUTHOR).</p> <p>Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables. <i>Expert Opin Pharmacother</i>. 2018 Mar;19(4):387-395. DOI: 10.1080/14656566.2018.1434143. (CO-AUTHOR)</p> <p>First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. <i>Curr Med Res Opin</i>. 2018 Oct;34(10):1803-1807. DOI:10.1080/03007995.2018.1451311. (CO-AUTHOR)</p> <p>Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. <i>Neurology</i>. 2018 May 1;90(18):852- 854. DOI: 10.1212/WNL.0000000000005417. (FIRST AUTHOR)</p> <p>Plasma Neurofilaments correlate with Disability in Progressive Multiple Sclerosis patients. <i>Acta Neurol Scand</i>. 2020 Jan;141(1):16-21. DOI: 10.1111/ane.13152. (CO-AUTHOR)</p> <p>Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Mult Scler Relat Disord</i>. 2020 Jan; 37:101461. DOI: 10.1016/j.msard.2019.101461. (CO-AUTHOR)</p> <p>Cerebrospinal fluid free light kappa and lambda chains in oligoclonal band-negative patients with suspected Multiple Sclerosis. <i>Eur J Neurol</i>. 2020 Mar;27(3):461-467. DOI: 10.1111/ene.14121. (CO-AUTHOR)</p> <p>Diagnostic features of initial demyelinating events associated with serum MOG-IgG. <i>J Neuroimmunol</i>. 2020 Jul 15; 344:577260. DOI: 10.1016/j.jneuroim.2020.577260. (CO-AUTHOR)</p> <p>Kappa Index Versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders. <i>Diagnostics (Basel)</i>. 2020 Oct 21;10(10):856. DOI: 10.3390/diagnostics10100856. (CO-AUTHOR)</p> <p>A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. <i>Journal of the Neurological Sciences</i>. 2021 March 424:117430. DOI: 10.1016/j.jns.2021.117430. (CO-AUTHOR)</p> <p>Early predictors of disability of paediatric-onset AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery, and Psychiatry</i>. 2021 Sep 28;jnnp-2021-327206. doi: 10.1136/jnnp-2021-327206 (FIRST AUTHOR)</p> <p>Kappa index in patients with autoimmune encephalitis. <i>Journal of the Neurological Sciences</i>. 2021. https://doi.org/10.1016/j.jns.2021.118795 (CO-AUTHOR)</p> <p>Frequency of New Silent MRI lesions in Myelin-Oligodendrocyte-Glycoprotein antibody disease and Aquaporin-4 antibody Neuromyelitis Optica Spectrum Disorder. <i>JAMA Netw Open</i> 2021 Dec 1;4(12):e2137833. doi:</p> |
|----------------------------|---|

| | |
|--|--|
| | <p>10.1001/jamanetworkopen.2021.37833 (FIRST AUTHOR)</p> <p>The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis. Mult Scler J Exp Transl Clin 2021 Dec 22;7(4):20552173211066446. doi: 10.1177/20552173211066446 (CO-AUTHOR)</p> <p>Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. Published online April 4, 2022. doi:10.1001/jamaneurol.2022.0489 (CO-AUTHOR)</p> |
|--|--|

| | |
|---|--|
| <p>SCIENTIFIC CONFERENCES (Please specify if presenter or co-author)</p> | <p>ORAL PRESENTATIONS:</p> <p>Resting-state and structural MRI metrics related to fatigue in MS, MOGAD and AQP4-NMOSD. European Charcot Foundation 29th Annual Meeting 2021 - Young Investigators session – Investigations – Session date:18-11-2021</p> <p>New T2 silent lesions in Myelin-Oligodendrocyte-Glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorders. Type: Oral Presentation. ECTRIMS-2021 - Scientific Session 1: NMO spectrum and MOG antibody associated disorders: distinctions and overlaps Session Date: 13-10-2021</p> <p>Early predictors of disability of paediatric-onset AQP4-IgG seropositive neuromyelitis optica spectrum disorders. International Women in MS: Global Conference. Session data: 02-08-2021</p> <p>POSTERS PRESENTATION:</p> <p>Significant increase of CD56⁺(bright) CD16⁻ NK cells observed in multiple sclerosis patients treated with Dimethylfumarate. Abstract P662; Type: Poster. ECTRIMS 2016-32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. (Presenter)</p> <p>Myocardial Ischemia associated with Alemtuzumab infusion in Multiple Sclerosis-a case report. Abstract: EP1725; Type: Eposter. ECTRIMS 2017 -33rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. (Presenter)</p> <p>Performance of the 2010 and 2017 revised McDonald criteria in an Italian retrospective cohort of patients with clinically isolated syndrome. Abstract: P973. Type: poster Sessions. ECTRIMS 2018-34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. (Presenter)</p> <p>Performance of the 2010 and 2017 revised McDonald criteria in an Italian retrospective cohort of patients with clinically isolated syndrome. Abstract: S444. XLIX of Italian Neurological Society. (Presenter)</p> <p>A case of MOG-IgG related aggressive encephalomyelitis: is it time to introduce a new nosological entity? Abstract. XLIX of Italian Neurological Society (Presenter)</p> <p>Characteristics and treatment of multiple sclerosis - related trigeminal neuralgia: an Italian multi-centre study. Abstract: P371. Type: Poster Session. ECTRIMS 2018-34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (co-author)</p> <p>Utility of cerebrospinal fluid free light kappa and lambda chain determination in oligoclonal band-negative patients with suspected multiple sclerosis. Abstract: P860. Type: Poster Session. ECTRIMS 2018 (co-author)</p> |
|---|--|

| | | |
|--|--|----------------|
| | <p>Management of multiple sclerosis - related trigeminal neuralgia in Italian centres. Abstract EP1382. Type: Poster Session.ECTRIMS 2018-34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – co-author)</p> <p>Kappa index versus cerebrospinal fluid IgG oligoclonal bands in everyday clinical practice: preliminary results of a prospective study. Abstract: P952. Type: Poser Sessions.ECTRIMS 2019-35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (co-author)</p> <p>Evaluation of the kappa index in patients with a single cerebrospinal fluid IgG band. Abstract: P953. Type: Poster Session.ECTRIMS 2019-35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (co-author)</p> <p>The MAGNIMS dissemination in space criteria: do they improve the 2017 McDonald criteria? Abstract: P348. Type: Poster Session.ECTRIMS 2019-35Tth Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Presenter)</p> <p>A case of MOG-IgG related aggressive encephalomyelitis: is it time to introduce a new nosological entity? Abstract; Type: Poster Session. XLIX of Italian Neurological Society (Presenter)</p> <p>Early predictors of disability of paediatric-onset AQP4-IgG seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery, and Psychiatry.ECTRIMS 2021- Poster ID P025. Poster Tour 5 – Clinical. <u>Top score Poster</u> (Presenter)</p> <p>Acute demyelinating events triggered by COVID-19 vaccines: case series.ECTRIMS 2021 -Poster ID P894. Poster Tour 4 – Therapies. <u>Top score Poster</u> (Presenter)</p> | |
| <p>AWARDS</p> | <p>Grant from European Charcot Foundation at Neuromyelitis Optica National centre, at John Radcliffe Hospital, Oxford, United Kingdom</p> <p>Travel grant -ECTRIMS 2019-3Tth Congress of the European Committee for Treatment and Research in Multiple Sclerosis</p> <p>Travel grant -ECTRIMS 2018-34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis</p> <p>Travel grant -ECTRIMS 2016-32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis</p> | |
| <p>LANGUAGES (Common European Framework Of Reference For Languages)</p> | <p>Italian</p> | <p>English</p> |

| | | | |
|-----------------------|---|----|--|
| Reading | mothertongue | C2 | |
| Writing | mothertongue | C2 | |
| Speaking | mothertongue | C1 | |
| COMPUTER | | | |
| Programming Language | Linux - UNIX | | |
| Software | <p>FMRIB Software library - independency in MRI data analysis – Attending and passing final exams of “FSL graduate course” from May 2020 to May 2021 at Wellcome Centre for Integrative Neuroimaging (WIN), FMRIB Centre, Nuffield Department of Clinical Neurosciences (NDCN), University of Oxford.</p> <p>STATA statistical software advanced level of independency – attended course “STATA: statistical analysis and graph”; IT learning Centre, University of Oxford</p> <p>R statistical software – basic level of independency- attended course “R: A first Sight”; IT learning Centre, University of Oxford</p> <p>MatLab – basic level of independency</p> <p>Access Microsoft data software – moderate level of independency</p> | | |
| Other Titles | <p>GCP – Good Clinical Practice Certificate for conducting clinical trials</p> <p>Registered with right to practice at General Medical Council, United Kingdom - GMC number: 7901426 (May 2021)</p> <p>Member of the Steering Committee of European Charcot Foundation Young Investigators community</p> | | |
| Hobbies and Interests | Hiking, rock-climbing, reading books, running, cinema, music | | |